Skip to main content

Day: March 24, 2022

Epsilon Energy Ltd. Announces Full Year 2021 Results

HOUSTON, March 23, 2022 (GLOBE NEWSWIRE) — Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported its financial results for the fourth quarter and full-year ended December 31, 2021. Epsilon’s highlights for 2021 and material subsequent events following year end through the date of this release include:Total Revenues of $42.4 million for the year as compared to $24.4 million for the same period of 2020.Net after tax income of $11.6 million ($0.49 per share) for the year as compared to $0.9 million ($0.03 per share) for the same period of 2020.Adjusted EBITDA of $24.1 million for the year as compared to $15.7 million for the same period of 2020.Average net natural gas prices of $2.68/Mcf including hedges ($3.10/Mcf excluding hedges) for the year as compared to $1.78/Mcf including hedges ($1.36/Mcf...

Continue reading

Sabina Gold & Silver Announces Financial Results for the Year Ended December 31, 2021

VANCOUVER, British Columbia, March 23, 2022 (GLOBE NEWSWIRE) — Sabina Gold & Silver Corp. (“Sabina”) or (the “Company”) (SBB – TSX) reports the financial results for the year ended December 31, 2021. “2021 was a year of continued de-risking at the Back River Project,” said Bruce McLeod, the Company’s President & CEO. “We were able to complete approximately 40% of the project’s civil works in preparation for a construction decision. Ongoing work completed at the Goose Site included advancement of the all-weather road network, significant progress of the plant, fuel storage and camp laydown areas and advancement on the underground exploration ramp. Additionally, significant commitments for equipment and supply purchases continued to be made. All of this work, along with completion of detailed engineering with costs well...

Continue reading

argenx raises $700 million in gross proceeds in a global offering

Regulated information — Inside information    March 23, 2022, 9:00 PM ET March 24, 2022, 2:00 AM CET   Breda, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced today the pricing of a global offering of ordinary shares represented by American Depository Shares (“ADSs”) in the United States and certain other countries outside of the European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area and the United Kingdom. The Company anticipates total gross proceeds of approximately $700 million (approximately €637 million) from the sale of 1,551,044 ADSs at a price of $300.00 per ADS and the sale of 782,290 ordinary shares at a price of €273.10 per ordinary share....

Continue reading

Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board

NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Philip R. Krause, M.D. has joined its Board of Directors. Dr. Krause was for the past decade Deputy Director, Office of Vaccines Research and Review (OVRR) at the US Food and Drug Administration (FDA)’s Center for Biologics Evaluation and Research (CBER). Dr. Krause is currently Chair of the World Health Organization COVID Vaccines Research Expert Group, and most recently he shared responsibility for regulatory authorizations of COVID-19 vaccines in the US. His experience encompasses regulation and development of biological products, including interdisciplinary team-based review process for clinical (safety and efficacy) and CMC (product quality) issues...

Continue reading

Rani Therapeutics to Release Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 29, 2022

SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company will release fourth quarter and full year 2021 financial results on Tuesday, March 29, 2022 after the close of market. Rani will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business update. Individuals interested in listening to the live conference call may do so by dialing (844) 605-7369 for domestic callers, or (929) 517-0917 for international callers and reference conference ID: 7192045; or from the webcast link in the investor relations section of the company’s website at: www.ranitherapeutics.com. A...

Continue reading

Verisk Estimates Insured Industry Losses for M7.3 Namie, Japan, Earthquake

BOSTON, March 23, 2022 (GLOBE NEWSWIRE) — According to Verisk Extreme Event Solutions (formerly AIR Worldwide), insured losses to properties from the March 16 M7.3 earthquake that struck offshore the island of Honshu, Japan, will be between JPY 240 billion (~USD 2 billion) and JPY 490 billion (~USD 4 billion). Of that, between JPY 50 billion (~USD 400 million) and JPY 100 billion (~USD 820 million) can be attributed to commercial and industrial properties. Early reports suggest that more than 580 buildings in Fukushima Prefecture and more than 570 buildings in Miyagi Prefecture were damaged. Other impacts from the quake include power and water outages; damage to highways, rail lines, viaducts, and other infrastructure; short-term cancellation of some train service; and significant supply chain and production interruption for the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.